Member Info for gtc1507

There's a £20k buy at 0800

No one can be sure in this world, but I'm happy holding here to see what comes

Looks like a full allowance buy of £20k this morn first thing. good to see the confidence. I'm confident we'll see positive news soon

According to their LinkedIn they're heading to the American Association of Cancer Research conference in San Diego this Friday. Mitchell hos lab features heavily on the agenda wonder will we see a meet up and an update on NCI negotiations/contract conclusion

Trading update could land any day now, exciting period as we get confirmation or otherwise of whether they're going to hit the around 70-80% growth in revenues that brokers are looking for as well as insight into how well optimal is landing. Should get an investor meet too if they go with same pattern as previous years

As much as it pains me to say it, I agree with Rocka, focus on fab and not him 🤣

Looks like a bed and isa type thing hasn't affected the price

Agreee / there's strong demand out there was a very strong close and Nt to buy for any real amount this morning. I say the rise hopefully keeps coming into news

Getting interesting now - NT to buy again

They do love a Thursday rns

It started in May last year so we're in the tail end now. You'd hope they would be Making good progress. My understanding from the webinars is they're on a strict project plan to align with the grant funding also.

The company actually did a helpful video on this DR5 project.

https://investorhub.fusionantibodies.com/activity-updates/rkE32y-deep-dive-series-dr5

According to the video, they already have a working antibody and the 18-month programme (with Innovate UK funding alongside Queen’s University Belfast) is about getting it clinic-ready — humanised, manufacturable and validated in vivo.

What stood out to me in that vid is that apparently big pharma have been trying to crack DR5 for years (AstraZeneca, Genmab, Genentech all have programmes), but nothing has made it past Phase 2 and there are still no approved drugs.

According to the video, the issue is that DR5 only works if you activate three receptors together (trimerisation), and most antibodies haven’t been able to do that properly without complex engineering.

So others have had to use more complicated formats (IgM, hexamers, etc), which adds risk and hasn’t translated well clinically.

According to the video, Fusion’s antibody can trigger this naturally without extra cross-linking or complex formats, and when compared to failed antibodies it showed much stronger cell-killing activity.

If that holds up, it’s essentially addressing the main reason previous approaches struggled.

End goal here isn’t to run trials themselves — it’s to get to a clinic-ready asset and license it out.

So based on what they’ve said:

• Validated cancer target with major pharma interest

• Known technical challenge that’s held the field back

• Their antibody designed specifically to overcome that

If they can deliver what’s outlined in the video, you can see why this could be an attractive licensing opportunity.

That's the ideal scenario isn't it. Prove their technology works and generate assets for someone else to develop.

This is what's on the Innovate UK website about the DR5 project - I think due to conclude later this year.

"**Targeting DR5: a New Cancer Treatment Strategy**

Cancer cells are like rogue agents in the body that don't follow the usual rules. To tackle these dangerous cells, scientists have found a special pathway involving a protein called **Death Receptor 5 (DR5)** (Alternative names: Tumor necrosis factor receptor superfamily member 10B; TNFRSF10B; TRAIL receptor 2; TRAIL-R2; CD262), which can tell cancer cells to self-destruct.

The goal of this project is to create a new type of treatment that specifically targets DR5 to trigger the death of cancer cells. This treatment uses an "agonistic antibody", which means it can activate DR5 in a way that encourages cancer cells to die, without harming healthy cells. This selective action could lead to fewer side effects compared to traditional treatments like chemotherapy.

**What Makes This Project Special?** Fusion Antibodies and Queen's University Belfast (QUB) have already developed a prototype of this new antibody that stands out from other similar treatments from an MRC CAST studentship. In this project, they aim to refine and test this prototype to ensure it's safe and effective for patient use---a process known as "humanization".

**The Plan:**

1\.**Design and refine the antibody** at Fusion Antibodies.

2\.**Test the antibody in preclinical studies** at QUB's Patrick G Johnston Centre for Cancer Research.

3\.**Conduct preliminary safety evaluations** to ensure the antibody is safe for human use.

The end result will be a well-tested antibody ready for clinical trials. This new treatment option could either be developed further by Fusion Antibodies and QUB or licensed to a pharmaceutical company for widespread use, ultimately benefiting patients with various types of cancer."

I forgot about DR5 - we know Richard was presenting an update on how that's developing at the UKRI launchpad conference a couple of weeks ago. That's good

Agree let's not detract from them! There's a positive story to tell here and plenty of potential news catalysts to come. For me we're hopefully going to see positive news soon on the following fronts:

- Confirmation of strong growth in h2.

- Movement on the licensing agreement for Optiphage?

-Update or confirmation of the NCI deal - we last got this when they were in San Diego and they're there again next weekend.

-The first optimal contract confirming the r&d and market research was good.

-Potential updates from their partnership with the future medicine institue

-Potential updates from their AI/ML partnership with Oxford Uni and professor Charlotte Deane.

-Traction on their IP portfolio with further applications under scrutiny in Europe and Asia after securing the US patent. That would complete the global triad.

Lots of potential catalysts to come and all while they're cashed up with VC and II backers

Couple of sellers better they're gone when the news comes

15p paid, someone wants these bad

Nice to see buyers paying over ask this morning

S&P XBI biotech index set to open at 133, its highest level since August 2021 back when the funding environment for FAB was much better and they inked around 4.5m revenues that year. Hopefully we see evidence of a strong recovery in the year end update